Skip to main content
Hikal Ltd. logo

Hikal Ltd. — Investor Relations & Filings

Ticker · HIKAL ISIN · INE475B01022 LEI · 335800OLTGHHYZWTF859 BSE.NS Manufacturing
Open in API
Filings indexed 715 across all filing types
Latest filing 2023-02-02 Regulatory Filings
Country IN India
Listing BSE.NS HIKAL

About Hikal Ltd.

https://www.hikal.com

Hikal Ltd. provides solutions across the life sciences value chain, specializing in the development and manufacturing of active ingredients, intermediates, and formulations. The company operates through two primary business segments: Pharmaceuticals and Crop Protection. In the pharmaceutical division, it focuses on the production of Active Pharmaceutical Ingredients (APIs) and advanced intermediates for various therapeutic areas. The crop protection segment involves the contract manufacturing of pesticides, herbicides, and fungicides for global agrochemical leaders. Hikal offers comprehensive Contract Research and Manufacturing Services (CRAMS), leveraging its research and development capabilities to support clients from early-stage development to commercial-scale production. Its facilities adhere to international quality standards, maintaining a strong track record of regulatory compliance with global health authorities.

Recent filings

Filing Released Lang Actions
Investor Presentation
Regulatory Filings
2023-02-02 English
Press Release
Earnings Release Classification · 95% confidence The document is an earnings press release dated February 2, 2023, announcing the unaudited standalone and consolidated financial results for the quarter and period ended December 31, 2022. It includes key financial highlights such as revenue, EBITDA, PAT, segment-wise revenue performance, and management commentary on the quarter's performance. The document is not a full quarterly report but an initial announcement of quarterly financial results with key highlights and commentary. It is not a full Annual Report, Interim Report, or Management Discussion & Analysis. The presence of financial results for a quarter and the nature of the document as a press release aligns with the definition of an Earnings Release (ER). The document length (9172 characters) supports it being a detailed earnings release rather than a brief announcement or a full report.
2023-02-02 English
Dividend
Regulatory Filings
2023-02-02 English
Financial Result Updates
Regulatory Filings
2023-02-02 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 60% confidence The document is an announcement dated January 30, 2023, informing about an upcoming earnings conference call scheduled for February 2, 2023, to discuss the financial and operational performance for the quarter and nine months ended December 31, 2022. It includes details such as dial-in numbers, participants, and RSVP contacts. There are no actual financial statements or substantive financial data presented in the document; it is purely an invitation and notification of the earnings call event. According to the classification rules, such documents are classified as Call Transcript (CT) only if they contain the full transcript of the call. Since this is only an announcement of the call, it does not qualify as a transcript. It is also not a report publication announcement or regulatory filing. The best fitting category is Call Transcript (CT) as it relates directly to the earnings call event, but since it is only an announcement, the confidence is moderate.
2023-01-30 English
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 95% confidence The document is a notice from Hikal Limited addressed to stock exchanges about a scheduled Board Meeting on February 2, 2023. The notice states that the Board will consider and approve the unaudited financial results for the quarter ended December 31, 2022, and also consider payment of an interim dividend. The document is short (1635 characters) and serves as an announcement of an upcoming board meeting and financial results approval, not the financial results report itself. It does not contain actual financial data or detailed financial statements. Therefore, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement informing the market about the board meeting and agenda, rather than the financial report or dividend notice itself.
2023-01-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.